Ozempic (semaglutide) is FDA-approved specifically for type 2 diabetes management
LIMITATIONS, REASONS FOR CAUTION Study limitations include the absence of data regarding medication compliance post prescription redemption, potential misclassification due to parallel importation, and the inability to control for unmeasured confounding factors
Separately, under the Medicare Drug Price Negotiation Program, CMS negotiated a $274-a-month price for Ozempic, Wegovy and Rybelsus, set to take effect in 2027
Certain Antibiotics (e.g., ciprofloxacin, levofloxacin): May affect blood sugar levels
They are not FDA-approved for cosmetic skin whitening, and evidence is still evolving which is why medical supervision and realistic expectations matter
Therapeutic effects of paeoniflorin on irritable bowel syndrome in rats